In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae

ABI-1648 (rifalazil) is a semisynthetic rifamycin with potent bactericidal activity against intracellular respiratory bacteria, including Mycobacterium tuberculosis, and a long half-life (∼60 h) and thus can be administered once weekly. We therefore tested the in vitro activities of ABI-1648, its de...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Roblin, Patricia M., Reznik, Tamara, Kutlin, Andrei, Hammerschlag, Margaret R.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Microbiology 2003
נושאים:
Susceptibility
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC149300/
https://ncbi.nlm.nih.gov/pubmed/12604555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.47.3.1135-1136.2003
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים